Bli medlem
Bli medlem

Du är här


Elekta: Elekta announces strategic partnership with the Centre hospitalier de l'Université de Montréal

Cancer treatment equipment and oncology information system to increase
efficiency and standard of treatment

MONTREAL, Canada, May 7 - Elekta has signed an agreement to provide
the Centre hospitalier de l'Université de Montréal* (CHUM) with
advanced linear accelerators and software. The order, resulting from
a competitive tender process, is valued at more than USD 20 million
and was booked during Elekta's fourth quarter of its fiscal year

The CHUM was formed through the merger of three teaching hospitals,
including the 372-year old Hôtel-Dieu Hospital. It is one of the
largest hospitals in Canada and a leading academic center in the
province of Quebec. To increase the efficiency of its new integrated
cancer center, the CHUM has chosen Elekta's MOSAIQ®
oncology information system to manage the complete spectrum of
oncology treatments in a single patient record accessible by its 17
multi-disciplinary teams across multiple locations.

The partnership agreement also includes Elekta Infinity™
linear accelerators with Agility™
multileaf collimators. At the core of a new radiotherapy treatment
platform, this sophisticated technology will offer CHUM's clinicians
superior dose conformance and treatment speed as well as
high-resolution beam shaping. For patients, it means safer, faster
treatment with less risk of damage to healthy tissue.

Dr. David Roberge, Head of Radiation Oncology at CHUM, says: "We chose
Elekta, not simply for the advanced capabilities of its linear
accelerators, but because of our shared vision for improving cancer
management. Together, we will better integrate our cancer care
activities - whether it be clinical research, screening, surgery,
systemic therapy, radiation, survivorship or palliative care. MOSAIQ
will ensure that patients have the most efficient management options

Jay Hoey, Executive Vice President of Region North America, says:
"This is another example of how Elekta is aligning with comprehensive
cancer programs to lead the future of cancer care together. We hope
to establish MOSAIQ as the primary electronic medical record solution
for cancer care across the province, thereby enhancing the experience
for cancer patients and providers."

Michael Power, Vice President and Managing Partner for Elekta Canada,
says: "Elekta is already well positioned in Quebec, and with this
strategically important partnership, our commitment to the region
will be even stronger."

*University of Montreal Health Centre

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta

Tel: +31 653 561 242, e-mail:
Time zone: CET: Central European Time
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail:
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public
in accordance with the Securities Market Act and/or the Financial
Instruments Trading Act. The information was published at 07:30 CET
on May 7, 2014.

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The
company develops sophisticated, state-of-the-art tools and treatment
planning systems for radiation therapy, radiosurgery and
brachytherapy, as well as workflow enhancing software systems across
the spectrum of cancer care. Stretching the boundaries of science and
technology, providing intelligent and resource-efficient solutions
that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over
6,000 hospitals worldwide. Elekta employs around 3,500 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on the Nordic Exchange under the ticker
STO:EKTAB. Website:


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.